American Oriental Bioengineering, Inc. Announces Inclusion in New PRC Government Sponsored Initiative.

* The Company's Cease Enuresis Soft Gel and Jinji Series of Products are some of the First Plant-Based Pharmaceuticals Added

NEW YORK -- American Oriental Bioengineering, Inc. (AMEX: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, announced today that two of the Company's leading products, Cease-Enuresis Soft Gel and Jinji Gel, have been selected to join in the International Traditional Chinese Medicine ("TCM") Program For Cooperation In Science and Technology. This newly established program is a long-term, collaborative effort between three of China's state regulatory bodies, the Ministry of Science and Technology, the Ministry of Health, and the State Administration of Traditional Chinese Medicine.

TCM have been used within China for thousands of years and the objective of this program is to further enhance the development of the industry by supporting some of the existing top echelon companies to promote the benefits not only within China but also potentially internationally. Over one thousand TCM products were evaluated by the aforementioned government agencies and only thirty of them were selected during the first phase of the program. The process for inclusion was rigorous with central government experts, local authorities and highly-regarded institutions responsible for the group's final conclusions. Over time, selected companies will receive support from dedicated science and health personnel from the government agencies to augment their R&D efforts with an aim to improve the selected products to reach international standard and possible future globalization.

"We are extremely pleased that two of our leading products were selected to be part of this elite group of Traditional Chinese Medicine products," commented Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering. "This selection highlights the quality of our products and further demonstrates our leadership in the plant-based pharmaceutical category. Today's announcement also helps us gain increased product awareness among existing and new points of distribution, especially for our Cease-Enuresis Soft Gel and Jinji Gel products."

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. (AOB) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.